Cutaneous Squamous Cell Carcinoma Staging Study
Launched by QUEEN MARY UNIVERSITY OF LONDON · Jan 20, 2023
Trial Information
Current as of May 12, 2025
Recruiting
Keywords
ClinConnect Summary
The Cutaneous Squamous Cell Carcinoma Staging Study is a clinical trial aimed at improving how we predict the outcomes for patients with cutaneous squamous cell carcinoma (CSCC), which is a type of skin cancer. While most cases of CSCC can be treated successfully with surgery, some can be more serious and may spread to other parts of the body. This study will examine existing cases of CSCC from two dermatology centers in the UK to see how well current staging systems can predict which patients may have a higher risk of poor outcomes. In the second part of the study, the researchers will look for better tools to make these predictions.
To participate in this trial, you must be at least 18 years old and have been diagnosed with CSCC. If you agree to let your data be used for research, you could help improve the way doctors manage and treat this condition. Participants can expect to be part of a study that may lead to better understanding and treatment options for future patients with CSCC. The trial is currently recruiting patients of all genders, and your involvement could make a significant difference in skin cancer research!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years old with diagnosis of CSCC
- Exclusion Criteria:
- • Patients who decline for their data to be used for research purposes
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials